Carac, Efudex, Fluorouracil

Carac, Efudex, Fluorouracil Newswire

Comprehensive Real-Time News Feed for Carac, Efudex, Fluorouracil (generic).

Results 1 - 20 of 120 in Carac, Efudex, Fluorouracil (generic)

  1. Health mystery: Overdose of chemo'Read the original story w/Photo

    3 hrs ago | Stuff.co.nz

    After a CT scan revealed a severely inflamed colon, Kathy Lang Albright told a nurse that she felt her "guts were disintegrating." The memories remain so vivid that Kathy Lang Albright still goes out of her way to avoid driving past the clinic where she received her first chemotherapy treatments.

    Comment?

  2. Medical Mysteries: Toxic chemotherapyRead the original story w/Photo

    Friday May 22 | The Washington Post

    The memories remain so vivid that Kathy Lang Albright still goes out of her way to avoid driving past the clinic where she received her first chemotherapy treatments. When Ebola was dominating the news, just hearing about the gastrointestinal symptoms of the disease made her weep, as she recalled the hellish weeks when the aftereffects of her treatment seemed worse than the advanced colon cancer it was designed to treat.

    Comment?

  3. Tumor regression and survival after perioperative MAGIC-style...Read the original story

    Thursday May 21 | BioMed Central

    This is an Open Access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver applies to the data made available in this article, unless otherwise stated.

    Comment?

  4. Pegylated liposomal doxorubicin (Lipo-Dox ) combined with...Read the original story

    Thursday May 21 | BioMed Central

    Pegylated liposomal doxorubicin combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study Division of Hematology-Oncology, Department of Internal Medicine, LinKo Chang Gung Memorial Hospital, 5, Fushing St., Gueishan Township, Taoyuan 333, Taiwan The electronic version of this article is the complete one and can be found online at:

    Comment?

  5. Drug combination lengthens lives of metastatic colorectal cancer patientsRead the original story w/Photo

    Friday May 15 | Medical News

    A drug developed 50 years ago and abandoned because it was considered to be too toxic has gained a second life in an international clinical trial. Research led by scientists at Dana-Farber Cancer Institute showed the drug and a potentiating agent lengthened the lives of patients with metastatic colorectal cancer, all of whom had exhausted available standard treatments.

    Comment?

  6. New Drug Combination Extends Survival of Patients with Metastatic Colorectal CancerRead the original story

    Wednesday May 13 | Newswise

    A drug developed 50 years ago and abandoned because it was considered to be too toxic has gained a second life in an international clinical trial. Research led by scientists at Dana-Farber Cancer Institute showed the drug and a potentiating agent lengthened the lives of patients with metastatic colorectal cancer, all of whom had exhausted available standard treatments.

    Comment?

  7. Drug extends survival of patients with metastatic colorectal cancerRead the original story w/Photo

    Wednesday May 13 | PhysOrg Weblog

    A drug developed 50 years ago and abandoned because it was considered to be too toxic has gained a second life in an international clinical trial. Research led by scientists at Dana-Farber Cancer Institute showed the drug and a potentiating agent lengthened the lives of patients with metastatic colorectal cancer, all of whom had exhausted available standard treatments.

    Comment?

  8. New Drug Combination Extends Survival of Patients with Metastatic Colorectal CancerRead the original story

    Wednesday May 13 | Newswise

    A drug developed 50 years ago and abandoned because it was considered to be too toxic has gained a second life in an international clinical trial. Research led by scientists at Dana-Farber Cancer Institute showed the drug and a potentiating agent lengthened the lives of patients with metastatic colorectal cancer, all of whom had exhausted available standard treatments.

    Comment?

  9. Q&A: Hans CleversRead the original story w/Photo

    Wednesday May 13 | Nature

    In 2009, Hans Clevers and Toshiro Sato demonstrated a powerful new model to study development and disease: a three-dimensional 'organoid' derived from adult stem cells that replicates the structure of cells lining the intestine. More than 100 labs worldwide are now working with different types of organoid to study cancer and other diseases.

    Comment?

  10. Teva Announces Adrucil RecallRead the original story w/Photo

    Tuesday May 5 | Pharmaceutical Processing

    Teva Parenteral Medicines today announced a voluntary recall of eight lots of Adrucil 5 g/100 mL due to the potential presence of particulate matter identified as aggregate of silicone rubber pieces from a filler diaphragm and fluorouracil crystals. Administration of an intravenous product with particulate matter has the potential to result in inflammation, allergic reactions, or blockage of blood vessels, leading to tissue death, which may be life-threatening if vital organs are affected.

    Comment?

  11. Teva Parenteral Medicines Initiates Voluntary Nationwide Recall of...Read the original story w/Photo

    Monday May 4 | US Recall News

    Teva Parenteral Medicines today announced a voluntary recall of eight lots of AdrucilA 5 g/100 mL due to the potential presence of particulate matter identified as aggregate of silicone rubber pieces from a filler diaphragm and fluorouracil crystals. The Food and Drug Administration is an agency within the U.S. Department of Health and Human Services.

    Comment?

  12. Teva Parenteral Medicines Initiates Voluntary Nationwide Recall of...Read the original story

    Monday May 4 | US Food and Drug Administration

    FDA posts press releases and other notices of recalls and market withdrawals from the firms involved as a service to consumers, the media, and other interested parties. FDA does not endorse either the product or the company.

    Comment?

  13. Tocagen Inc. Presents Updated Interim Survival Data From Ongoing...Read the original story

    Sunday May 3 | BioSpace

    Tocagen Inc. Presents Updated Interim Survival Data From Ongoing Clinical Studies At American Association Of Neurological Surgeons / Congress Of Neurological Surgeons Section On Tumors /PRNewswire/ -- Tocagen Inc. , a clinical-stage immuno-oncology company, today announced updated interim data from Tocagen's ongoing investigational studies were presented at the 11th Biennial Satellite Symposium of the American Association of Neurological Surgeons /Congress of Neurological Surgeons Section on Tumors, held In addition, Tocagen announced the company held a meeting with FDA and continues to advance towards initiation of a pivotal, randomized, controlled Phase 2/3 trial of Toca 511 & Toca FC in patients with recurrent glioblastoma and recurrent anaplastic astrocytoma this year.

    Comment?

  14. Oncologists using viruses to treat brain cancerRead the original story w/Photo

    Wednesday Apr 29 | The Item

    The Neurological Oncology team at the John Theurer Cancer Center at HackensackUMC. From left to right: Samuel Goldlust, M.D., Neuro-Oncology; Stacey M. McArdle, AOCNP; Anthony Ingenito, M.D., Radiation Oncology; Samuel Singer, M.D., Neuro-Oncology; Eileen Beysel, BSN; George J. Kaptain, M.D., Neurosurgical Oncology; Lori Cappello, BSN; K. Daniel Lee, M.D., Neurosurgical Oncology; Brett E. Lewis, M.D., PhD, Radiation Oncology.

    Comment?

  15. Dyax Corp. Announces First Quarter 2015 Financial ResultsRead the original story

    Wednesday Apr 29 | Freshnews

    Dyax Corp. today announced financial results for the first quarter ended March 31, 2015. Dyax will host a webcast and conference call at 5:00 p.m. today to review financial results and provide updates regarding its key value drivers - including DX-2930, KALBITOR , and the Licensing and Funded Research Portfolio .

    Comment?

  16. Correlation of Aurora-A expression with the effect of chemoradiation ...Read the original story

    Tuesday Apr 28 | BioMed Central

    Kiyokazu Tamotsu , Hiroshi Okumura *, Yasuto Uchikado , Yoshiaki Kita , Ken Sasaki , Itaru Omoto , Tetsuhiro Owaki , Takaaki Arigami , Yoshikazu Uenosono , Akihiro Nakajo , Yuko Kijima , Sumiya Ishigami and Shoji Natsugoe Department of Digestive Surgery, Breast and Thyroid Surgery, Graduate School of Medical Sciences, Kagoshima University, Sakuragaoka 8-35-1, Kagoshima 890-8520, Japan Background Chemoradiation therapy is one of the most useful treatments for esophageal squamous cell carcinoma . However, because some patients respond well to CRT and others do not, it is important to be able to predict response to CRT before beginning treatment by using markers.

    Comment?

  17. PharmaEngine, Inc. Announces Merrimack Completed MM-398 (PEP02) New...Read the original story

    Monday Apr 27 | BioSpace

    PharmaEngine, Inc. today announced that its licensing partner, Merrimack Pharmaceuticals, Inc. has completed the rolling submission of the New Drug Application for MM-398 to the U.S. Food and Drug Administration in patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. Merrimack also announced that they have requested priority review of the MM-398 NDA by the FDA.

    Comment?

  18. Cyramza (Ramucirumab) Receives Fourth FDA ApprovalRead the original story

    Monday Apr 27 | P&T Community

    Cyramza has received its fourth FDA approval. The drug is now indicated in combination with Folfiri chemotherapy for the treatment of patients with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.

    Comment?

  19. Annapolis Valley cancer care advocate Robin McGee wins her gold medal this weekRead the original story w/Photo

    Sunday Apr 26 | Nova News Now

    The Canadian Cancer Society will present their National Medal of Courage to Cancer Olympics author Robin McGee of Port Williams on Wednesday morning. McGee, who battled colorectal cancer and medical indifference, gets a gold medal for her efforts.

    Comment?

  20. Local pelvic irradiation modulates Pharmacokinetics of...Read the original story

    Apr 25, 2015 | BioMed Central

    Background 5-fluorouracil is employed to enhance radiotherapy effect. Here, we evaluated the influence of whole-pelvic irradiation on the pharmacokinetics of 5-FU in plasma and lymphatic system of rats as the experimental model.

    Comment?